JP2016531910A - 移植前の臓器への補体阻害剤の投与による移植拒絶の処置 - Google Patents

移植前の臓器への補体阻害剤の投与による移植拒絶の処置 Download PDF

Info

Publication number
JP2016531910A
JP2016531910A JP2016534873A JP2016534873A JP2016531910A JP 2016531910 A JP2016531910 A JP 2016531910A JP 2016534873 A JP2016534873 A JP 2016534873A JP 2016534873 A JP2016534873 A JP 2016534873A JP 2016531910 A JP2016531910 A JP 2016531910A
Authority
JP
Japan
Prior art keywords
organ
complement
transplantation
complement inhibitor
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016534873A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016531910A5 (enExample
Inventor
イ ワン，
イ ワン，
ザオ シュエ ユー，
ザオ シュエ ユー，
Original Assignee
アレクシオン ファーマシューティカルズ， インコーポレイテッド
アレクシオン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクシオン ファーマシューティカルズ， インコーポレイテッド, アレクシオン ファーマシューティカルズ， インコーポレイテッド filed Critical アレクシオン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2016531910A publication Critical patent/JP2016531910A/ja
Publication of JP2016531910A5 publication Critical patent/JP2016531910A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
JP2016534873A 2013-08-16 2014-08-15 移植前の臓器への補体阻害剤の投与による移植拒絶の処置 Pending JP2016531910A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361867009P 2013-08-16 2013-08-16
US61/867,009 2013-08-16
PCT/US2014/051323 WO2015023972A1 (en) 2013-08-16 2014-08-15 Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant

Publications (2)

Publication Number Publication Date
JP2016531910A true JP2016531910A (ja) 2016-10-13
JP2016531910A5 JP2016531910A5 (enExample) 2017-09-28

Family

ID=51494495

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016534873A Pending JP2016531910A (ja) 2013-08-16 2014-08-15 移植前の臓器への補体阻害剤の投与による移植拒絶の処置

Country Status (5)

Country Link
US (1) US20160184391A1 (enExample)
EP (1) EP3033093A1 (enExample)
JP (1) JP2016531910A (enExample)
CA (1) CA2920293A1 (enExample)
WO (1) WO2015023972A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021532838A (ja) * 2018-08-17 2021-12-02 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア ドナー臓器における糖鎖抗原除去のための酵素組成物、それに関連する方法および使用
JP2022527126A (ja) * 2019-04-10 2022-05-30 ユニバーシティ オブ マサチューセッツ Ｈ因子ベクターおよびその使用

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
CA2840270C (en) * 2011-06-22 2023-09-26 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
EP3368073B1 (en) * 2015-10-30 2024-05-15 Alexion Pharmaceuticals, Inc. A method of inhibiting exacerbations of t cell-mediated allograft vasculopathy
CN108401431B (zh) 2015-12-18 2022-01-25 中外制药株式会社 抗-c5抗体及使用方法
WO2017212391A1 (en) * 2016-06-07 2017-12-14 Novartis Ag An anti-c5 antibody dosing regimen
EP3463459A1 (en) * 2016-06-07 2019-04-10 Novartis AG Tesidolumab for use in the treatment of transplant rejection
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
WO2018075462A1 (en) * 2016-10-17 2018-04-26 Medical University Of South Carolina Compositions and methods for treating and preventing transplant-associated injury
GB201709222D0 (en) * 2017-06-09 2017-07-26 Univ Manchester C3b Inactivating Polypeptide
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
WO2020041644A1 (en) * 2018-08-22 2020-02-27 Alexion Pharmaceuticals, Inc. Fusion proteins and methods of treating complement dysregulation using the same
JP7502805B2 (ja) * 2019-03-21 2024-06-19 ザ ユーエイビー リサーチ ファウンデイション 補体媒介性溶解に対する細胞感受性を増加させる方法
CN110423271A (zh) * 2019-08-07 2019-11-08 北京市农林科学院 鸡cr2基因的克隆、蛋白的表达和纯化及其多克隆抗体的制备
WO2021257480A2 (en) 2020-06-14 2021-12-23 Catalyst Biosciences, Inc. Complement factor i-related compositions and methods
AU2022283254A1 (en) * 2021-05-25 2023-11-30 Alexion Pharmaceuticals, Inc. Kidney active fusion proteins and methods of treatment using the same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10500289A (ja) * 1994-05-02 1998-01-13 アレクション・ファーマシューティカル・インク 糸球体腎炎および他の炎症性疾患の治療のための組成物および方法
JP2007527299A (ja) * 2004-03-05 2007-09-27 グローバル アプライアンス テクノロジーズ インコーポレイテッド コンベヤオーブン
JP2009528369A (ja) * 2006-03-02 2009-08-06 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体活性を抑制することによる同種移植片の生存の延長
JP2009540831A (ja) * 2006-06-21 2009-11-26 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 疾患の治療のための補体ｈ因子の標的化
JP2012508262A (ja) * 2008-11-10 2012-04-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体関連障害を処置するための方法および組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5723282A (en) 1991-07-08 1998-03-03 The American National Red Cross Method of preparing organs for vitrification
DE69535920D1 (de) 1994-05-20 2009-04-09 Breonics Inc Verfahren zur überwachung der lebensfähigkeit transplantabler organe
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
IL137614A0 (en) 1998-02-04 2001-07-24 Gen Hospital Corp An inhibitor of a costimulatory pathway and hematopoietic stem cells for promoting graft acceptance
AU1521000A (en) 1998-11-06 2000-05-29 Schepens Eye Research Institute, Inc., The Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye
AUPQ431299A0 (en) 1999-11-26 1999-12-23 Unisearch Limited Method of inducing immune tolerance
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
US20030180301A1 (en) 2002-01-22 2003-09-25 Shaf Keshavjee Use of TGF-beta antagonists to treat or to prevent chronic transplant rejection
EP2338511A3 (en) 2004-05-14 2012-07-25 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
US7745389B2 (en) 2005-02-14 2010-06-29 University Of Iowa Research Foundation Methods for treatment of age-related macular degeneration
US20130323708A1 (en) 2009-07-01 2013-12-05 Massachusetts Institute Of Technology Isolated adult cells, artificial organs, rehabilitated organs, research tools, organ encasements, organ perfusion systems, and methods for preparing and utilizing the same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10500289A (ja) * 1994-05-02 1998-01-13 アレクション・ファーマシューティカル・インク 糸球体腎炎および他の炎症性疾患の治療のための組成物および方法
JP2007527299A (ja) * 2004-03-05 2007-09-27 グローバル アプライアンス テクノロジーズ インコーポレイテッド コンベヤオーブン
JP2009528369A (ja) * 2006-03-02 2009-08-06 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体活性を抑制することによる同種移植片の生存の延長
JP2009540831A (ja) * 2006-06-21 2009-11-26 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 疾患の治療のための補体ｈ因子の標的化
JP2012508262A (ja) * 2008-11-10 2012-04-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体関連障害を処置するための方法および組成物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AM J PATHOL., 2003, VOL.163 NO.4, P.1457-1465, JPN6018015805, ISSN: 0004122559 *
低温医学, 2000, VOL.26 NO.4, P.195-201, JPN6019000814, ISSN: 0004122560 *
別冊 医学のあゆみ, 酸化ストレス−フリーラジカル医学生物学の最前線, 236-238, JPN6019000815, ISSN: 0003958150 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021532838A (ja) * 2018-08-17 2021-12-02 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア ドナー臓器における糖鎖抗原除去のための酵素組成物、それに関連する方法および使用
JP7684216B2 (ja) 2018-08-17 2025-05-27 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア ドナー臓器における糖鎖抗原除去のための酵素組成物、それに関連する方法および使用
JP2025131609A (ja) * 2018-08-17 2025-09-09 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア ドナー臓器における糖鎖抗原除去のための酵素組成物、それに関連する方法および使用
JP2022527126A (ja) * 2019-04-10 2022-05-30 ユニバーシティ オブ マサチューセッツ Ｈ因子ベクターおよびその使用
US12570997B2 (en) 2019-04-10 2026-03-10 University Of Massachusetts Factor H vectors and uses thereof

Also Published As

Publication number Publication date
WO2015023972A1 (en) 2015-02-19
CA2920293A1 (en) 2015-02-19
EP3033093A1 (en) 2016-06-22
US20160184391A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
US20160184391A1 (en) Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
KR101527225B1 (ko) 보체 활성을 저해함으로써 동종이식편의 생존 연장
JP5590624B2 (ja) 補体活性を阻害することによる同種移植片の生存の延長
US9839670B2 (en) Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins
US20250222127A1 (en) Compositions and methods for treating and preventing transplant-associated injury
WO2018075462A1 (en) Compositions and methods for treating and preventing transplant-associated injury
HK1120444B (en) Prolongation of survival of an allograft by inhibiting complement activity
AU2011236106A1 (en) Prolongation of survival of an allograft by inhibiting complement activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180502

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190415

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190927